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Abstract
Aim: We compared the clinical and physiological consequences of the novel
mutation R878C in a highly conserved pore residue in domain II (S5-S6) of
human, hNav1.5, cardiac Na
+ channels.
Methods: Full clinical evaluation of pedigree members through three gen-
erations of a Chinese family combined with SCN5A sequencing from
genomic DNA was compared with patch and voltage-clamp results from two
independent expression systems.
Results: The four mutation carriers showed bradycardia, and slowed sino-
atrial, atrioventricular and intraventricular conduction. Two also showed
sick sinus syndrome; two had ST elevation in leads V1 and V2. Unlike
WT-hNav1.5, whole-cell patch-clamped HEK293 cells expressing R878C-
hNav1.5 showed no detectable Na
+ currents (iNa), even with substitution of a
similarly charged lysine residue. Voltage-clamped Xenopus oocytes injected
with either 0.04 or 1.5 lg lL
)1 R878C-hNav1.5 cRNA similarly showed no
iNa, yet WT-hNav1.5 cRNA diluted to 0.0004–0.0008 ng lL
)1 resulted in
expression of detectable iNa. iNa was simply determined by the amount of
injected WT-hNav1.5: doubling the dose of WT-hNav1.5 cRNA doubled iNa.
iNa amplitudes and activation and inactivation characteristics were similar
irrespective of whether WT-hNav1.5 cRNA was given alone or combined
with equal doses of R878C-hNav1.5 cRNA therefore excluding dominant
negative phenotypic effects. Na
+ channel function in HEK293 cells trans-
fected with R878C-hNav1.5 was not restored by exposure to mexiletine
(200 lm) and lidocaine (100 lm). Fluorescence confocal microscopy using
E3-Nav1.5 antibody demonstrated persistent membrane expression of both
WT and R878C-hNav1.5. Modelling studies conﬁrmed that such iNa
reductions reproduced the SSS phenotype.
Conclusion: Clinical consequences of the novel R878C mutation correlate
with results of physiological studies.
Keywords cardiac Na
+ channels, novel mutation, pore-forming region,
SCN5A, sick sinus syndrome.
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a-subunit of the human cardiac Na
+ channel have been
associated with an increasingly wide range of cardiac
rhythmdisordersthatincludethelongQTsyndrometype
3 (LQT3), Brugada syndrome (BrS) and cardiac conduc-
tion diseases, idiopathic ventricular ﬁbrillation, sinus
node dysfunction including sick sinus syndrome (SSS),
atrialstandstillandsuddeninfantdeathsyndrome(SIDS)
(Akai et al. 2000, Benson et al. 2003, Groenewegen
et al. 2003, Tan et al. 2003, Wang et al. 2007). Further-
more, recent clinical reports, often associated with
physiological studies, suggest that particular mutations
in Na
+ channels result in a wide range of electrophysi-
ological changes as reﬂected in electrocardiographic
(ECG) studies. For example, the gain of function,
C-terminal SCN5A gene mutation (1795insD) in a large
Dutch family resulted in bradycardia, conduction dis-
ease, LQT3 and BrS (Bezzina et al. 1999, van den Berg
et al. 2001). Mice carrying its murine equivalent simi-
larly displayed bradycardia, right ventricular conduction
slowing and QT prolongation (Remme et al. 2006).
Conversely, loss of function mutations result in a
reduction in total iNa (Bennett et al. 1995, Chen et al.
1998, Tan et al. 2003). For example, the E161K muta-
tion in the Na
+ channel is correspondingly associated
withclinicalandECGfeaturesofBrS,conductiondisease
andsinusnodedysfunction(Smitset al.2005).Micewith
a single null mutation in Scn5a correspondingly show
reduced Na
+ channel function and electrophysiological
defects. These include impaired atrioventricular conduc-
tion, delayed intramyocardial conduction and ventri-
cular tachycardia with characteristics of re-entrant
excitation (Papadatos et al. 2002).
The present study identiﬁes and characterizes a novel
missense mutation of the highly conserved pore residue
arginine to cysteine R878C in domain II S5-S6 of the
cardiac Na
+ channel, and associates it with clinical
phenotypes that include ECG features of slowed atrio-
ventricular conduction, SSS, and ST elevations in the V1
and V2 leads in three generations of a Chinese family.
Our biophysical studies involving mutant channel
expression in either HEK293 cells or Xenopus oocytes
suggested that the above mutation similarly results in
non-functionalNa
+channels, therebyattributingclinical
ﬁndings of a wide range of phenotypes to a single
physiological alteration in Na
+ channel function. Func-
tion was not restored by the substitution R878K involv-
ing a similarly positively charged lysine reﬂecting a
critical function for the R878 residue. It was also not
restored by transient exposures to mexiletine (200 lm)
and lidocaine (100 lm), manoeuvres that have previ-
ously been used to restore channel trafﬁcking (Rajamani
et al. 2002, Valdivia et al. 2004, Anderson et al. 2006,
Cordeiro et al. 2006). Furthermore, we found that the
amount of measurable current is simply determined by
the level of expression of the WT-hNav1.5 channel:
R878C-hNav1.5 did not exert dominant negative phe-
notypic effects. Immunochemical studies suggested a
persistent membrane expression of both WT and mutant
Na
+ channels. Numerical simulations of the effect of the
mutant channel on sino-atrial (SA) node function then
reproduced the SSS phenotype. This analysis of the
R878C mutation thus extends from its clinical manifes-
tations to physiological characterization and modelling.
Methods
Clinical investigation
All investigations conformed to principles deﬁned in the
Helsinki Declaration. Seventeen members of a three-
generation Chinese family were investigated (see
Fig. 1a), informed written consent having been obtained
from each member. They included a full medical history,
physical examination, at least two 12-lead ECG record-
ings obtained at different times and echocardiographic
scanning. Heart rates, widths of P wave, PR intervals,
QRS durations and QT intervals, corrected for heart
rate (QTc), were measured in limb lead II (or lead I or III
if it could not be measured exactly with lead II) using
Bazett’s formula. QTc intervals were averaged from ﬁve
consecutive beats of at least two 12-lead ECG record-
ings at different time points. The presence or absence of
ST elevation was assessed using lead V2. Two 24-h
Holter-ECG recordings were performed in each of the
affected individuals. Two hundred unrelated control
individuals were randomly selected from a group of
Chinese healthy volunteers with normal 12-lead ECGs
and without reported cardiovascular history.
SCN5A mutation analysis
Genomic DNA was extracted from 10 mL of whole
blood using the Puregene Isolation kit (Gentra Systems,
Minneapolis, MN, USA). The coding regions of SCN5A
and exon/intron boundaries were ampliﬁed from geno-
mic DNA by polymerase chain reaction (PCR) using a
comprehensive set of primers and PCR conditions as
described previously (Wang et al. 1995, Syrris et al.
2001). Bidirectional sequencing was performed by an
ABI automated cycle sequencer using an ABI BigDye
Terminator Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA, USA). Sequencing results were aligned
with the respective wild-type (WT) sequences to detect
genetic variations. Identiﬁed mutation was screened in
the remaining family members by direct DNA sequenc-
ing. The mutations were further veriﬁed by single strand
conformational polymorphism (SSCP) analysis. The
same mutation was also screened in 200 controls with
the same ethnic background.
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mutant human Nav1.5
Plasmid pSP64T-hH1 coding for WT human Nav1.5
(hNav1.5 or hH1, accession No. M77235, kindly
provided by Dr A. L. George, Vanderbilt University,
TN, USA) was used as template for generating R878C
mutant Nav1.5 cDNA by recombinant PCR using the
primer pair 5¢-AAGGCATGAAAGAAGTCCATCAT-
GTGCCAGCAAGGCAGCAGGCCTGAGTC-3¢ (for
R878C). The PCR product was then inserted as
BseJI/Asp718I (R878C) fragment into the correspond-
ing site of the WT-hNav1.5 clone. The resulting DNA
construct was checked by restriction analysis, and
Asymptomatic mutation carrier 
2  1 
I
Mutation carrier only with V1 and V2 ST-T 
elevation 
Symptomatic mutation carrier 
Normal  
34 56 78   91 0   12  
II
Not evaluated 
6  5  4  3  2 7  1  89  
III
(a) 
(b) 
(e)
(c) 
(d) 
Figure 1 Pedigree and electrocardiographic features of the affected family. (a) Pedigree of the family with phenotypic and genotypic
information.Arrowindicatestheproband.(b,c)ECGandHolterdataofproband.(d)Twelve-leadECGofII-2;(e)12-leadECGofII-6.
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ing. Following XbaI digestion of the plasmid, capped
cRNA was prepared by in vitro transcription reaction
with SP6 RNA polymerase (Roche Diagnostics
GmbH, Mannheim, Germany). The WT-hNav1.5
was subcloned into a pEGFP expression vector. pEG-
FP-R878C-hNav1.5 was generated by site-directed
mutagenesis (QuickChange
TM Site-Directed Mutagene-
sis Kit; Stratagene, Cedar Creek, TX, USA) using
pEGFP-WT-hNav1.5 as the template for transfection
of HEK293 cells used in the biophysical studies.
Finally, WT-hNav1.5 was subcloned into pEGFP,
pEYFP and pECFP expression vector. pEGFP-
R878C-hNav1.5 and pEYFP-R878C-hNav1.5 were
generated as described above, using pEGFP-
WT-hNav1.5 and pEYFP-WT-hNav1.5 as templates,
respectively, and used for transfection of HEK293
cells for immunochemical staining visualized by
confocal microscopy.
Expression of human Nav1.5 in HEK293 cells and
Xenopus oocytes
HEK293 cells were cultured and transiently transfect-
ed, either in the presence or absence of the plasmid
for the b1 Na
+ channel subunit (also provided by
Dr A. L. George) using LipofectAMINE (Invitrogen,
Carlsbad, CA, USA) as described previously (Wang
et al. 2002). Oocytes were prepared from Xenopus
laevis and cRNA injection was performed according
to established procedures (Zimmer et al. 2002a). We
used two independent R878C hNav1.5 clones for
electrophysiological measurements. For current com-
parisons, the different cRNA samples were diluted in
order to adjust the cRNA concentration for each
variant to 0.04 ng lL
)1. In the case of R878C we
also injected undiluted cRNA at 1.5 lg lL
)1. Typ-
ical volumes of such injectates were between 40 and
60 nL. After 3 days of incubation at 18  C in Barth
medium, the peak current amplitude of the whole-cell
hNav1.5 current was usually between 0.5 and 6.0 lA.
Measurements were performed in at least three
different batches of oocytes.
Electrophysiological studies
For electrophysiological recordings, the HEK293 cells
were trypsinized 24 h after transfection and seeded
onto a glass coverslip to a density that enabled single
cells to be identiﬁed. Whole-cell Na
+ currents in
HEK293 cells were studied by patch-clamp recordings
with patch pipettes fabricated from borosilicate glass
capillaries (1.5 mm OD; Fisher Scientiﬁc, Pittsburgh,
PA, USA). The pipettes were pulled with a gravity
puller (model PP-830; Narishige, Tokyo, Japan) and
ﬁlled with a pipette solution of the following compo-
sition (in mm) KCl 10, CsF 105, NaCl 10, HEPES 10,
titrated to pH 7.2 with CsOH. Pipette resistance
ranged from 1.0 to 2.0 MW when pipettes were ﬁlled
with the internal solution. The perfusion solution
contained (in mm): NaCl 130, KCl 5, CaCl2 1.8,
MgCl2 1.0, sodium acetate 2.8, HEPES 10, and
glucose 10, titrated to pH 7.4 with NaOH. Current
signals were recorded with an Axon 200B ampliﬁer
(Axon Instruments, Foster City, CA, USA), and series
resistance errors were reduced by approximately
7080% with electronic compensation. Signals were
acquired at 20 kHz (Digidata 1200; Axon Instruments)
and analysed with a PC running pclamp 9 software
(Axon Instruments). All recordings were made at room
temperature (20–22  C). Whole-cell Na
+ currents in
Xenopus oocytes were recorded with the two-micro-
electrode voltage clamp technique using a commercial
ampliﬁer (OC725C; Warner Instruments, Hamden,
CT, USA), as previously described (Zimmer et al.
2002a). The glass microelectrodes were ﬁlled with 3 m
KCl. The microelectrode resistance was between 0.2
and 0.5 MW. The bath solution contained (in mm): 96
NaCl, 2 KCl, 1.8 CaCl2, 10 HEPES titrated to pH 7.2
with KOH. The currents were elicited by test poten-
tials from )80 to 40 mV using a holding potential of
)120 mV. The pulsing frequency was 1 Hz. Recording
and analysis of the data were performed on a PC with
iso2 software (MFK, Niedernhausen, Germany). The
sampling rate was generally 20 kHz.
Immunocytochemistry and imaging confocal microscopy
HEK293 cells expressing GFP-, CFP- and YFP-tagged
hNav1.5 were ﬁxed with 4% paraformaldehyde/PBS,
mounted with ﬂuorescent mounting medium (DakoCy-
tomation, Glostrup, Denmark) and viewed under con-
focal microscopy (LSMZ1; Carl Zeiss MicroImaging
GmbH, Berlin, Germany) at excitation wavelengths of
488 nm (for EGFP), 458 nm (for ECFP) and 514 nm
(for EYFP and Cy3). The immunocytochemistry stain-
ing using E3-targeted anti-Nav1.5 antibody (Ab)
and Cy3-conjugated secondary antibody (Chemicon,
Temecula, CA, USA) was performed as described previ-
ously (Xu et al. 2005). To achieve an optimal signal-
to-noise ratio for each ﬂuorescence signal, sequential
scanning with the speciﬁc wavelength was used.
Computer simulations
Computational studies attempting to simulate altera-
tions in heart rate using as a basis the biophysical
ﬁndings used here used an SA node/atrial model
established and implemented on previous occasions
(Lei et al. 2005).
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Data are presented as mean  SEM (number of cells).
Differences were evaluated by Student’s t-test and a
difference was considered signiﬁcant if P < 0.05.
Results
Clinical phenotypes and genetic analysis
Figure 1a summarizes the pedigree of the affected
family. Full medical histories, physical examinations,
echocardiographic scanning and ECG recording using
at least two 12-lead ECG recordings on two indepen-
dent occasions, were obtained from each member.
Finally, two 24-h Holter-ECG recordings were per-
formed in each of the genetically affected individuals.
The proband (subject III-5) was an 8-year-old boy who
presented with shortness of breath and exercise intol-
erance. His resting 12-lead ECG, corroborated by
oesophageal ECG recordings, showed a sinus bradycar-
dia with a heart rate of 40–60 beats min
)1 consistent
with SSS, atrial ectopics and widened QRS complexes
with a normal QTc (Fig. 1b). His 24 h Holter record-
ings revealed numerous sinus pauses whose longest
duration was 3.2 s (Fig.1c).
Subject II-2, one of the proband’s uncles, similarly
had a history of sinus bradycardia with a heart rate of
45–50 beats min
)1 and suffered multiple episodes of
syncope from his twenties. His resting ECG showed an
irregular sinus rhythm with long sinus pauses, a just-
demonstrable ﬁrst degree AV block, and ST-T eleva-
tion in leads V1 and V2 (Fig. 1d). The father of the
proband, subject II-6 was asymptomatic with a heart
rate of 60–65 beats min
)1 but had a resting ECG
showing ST-T elevation in leads V1 and V2 (Fig. 1e),
features conﬁrmed by four independent repeat ECGs
over 3 years. Both subject II-2 and subject II-6 had not
undergone any drug challenge tests directed at
unmasking BrS (Wilde et al. 2002). Finally, the
grandmother, subject I-2, was clinically and electro-
cardiographically normal. The remaining 14 family
members investigated were asymptomatic and had
normal ECGs. Table 1 compares ECG parameters
and clinical features of the mutation carriers and
non-carriers within the family concerned, demonstrat-
ing signiﬁcance differences in heart rate, P wave width,
PR interval, QRS duration and extent of ST elevation,
but not in QTc interval.
We ﬁrst screened the proband for SCN5A mutations
owing to their known association with familial SSS (Lei
et al. 2007). Having demonstrated genetic alterations in
the proband, we then similarly screened the remaining
family, with the exceptions of II-9, II-10, III-8 and III-9
who were not available for testing. The same mutation
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Acta Physiol 2008, 194, 311–323 Y Zhang et al.Æ Clinical and physiological consequences of a novel SCN5A mutationwas also screened in 200 controls with normal cardio-
vascular histories and clinical and ECG examinations
and the same ethnic background. DNA sequencing of
all the SCN5A exons and exon–intron boundaries
revealed a novel heterozygous base change in exon 16
(2826 C ﬁ T) (Fig. 2a; GenBank accession number:
DQ086162) in the proband, leading to the missense
mutation in which arginine, R, was replaced by cyste-
ine, C, at position 878 (R878C) (Fig. 2b); this was
further veriﬁed by SSCP analysis. Amino acid 878 is
located at the extracellular linker between transmem-
brane S5 and S6 in domain II (DII) of the Nav1.5
protein (Fig. 2c), which forms part of the channel pore,
consistent with an effect of mutation R878C on
permeation through Nav1.5 channels. Comparison of
aligned amino acid sequences that demonstrate that
R878 is highly conserved among different human Nav
channel isoforms (Fig. 2d). Furthermore, it is also
highly conserved among Scn5a in different, rat, mouse
and human species (Fig. 2e). We also found R878C in
II-2, II-6 and I-2 (Fig. 1a) but not in the remaining
members of the family studied. The functional conse-
quences of the R878C Nav1.5 were then investigated by
biophysical and modelling studies.
Biophysical characterization
The biophysical studies suggested that the above muta-
tion results in a loss of detectable Na
+ channel function.
Cells were clamped at a holding potential of )120 mV
and subjected to 30 ms duration depolarization pulses
between )110 and +50 mV in 5 or 10 mV increments at
pulse frequency of 1.0 Hz. First, HEK293 cells tran-
siently transfected with (0.5 lg) plasmid DNA for either
WT-hNav1.5 or R878C-hNav1.5 were investigated in
the whole-cell conﬁguration. Na
+ currents, iNa,
recorded from the HEK293 cells transfected with
plasmid for WT-hNav1.5 showed average peak current
densities of 432.2  49.16 pA pF
)1 (Fig. 3a,f) (n =1 0
cells). Similar currents were observed at a mean
peak level of 334.3  47.56 pA pF
)1 (n = 7 cells) with
transfection of half the dose of WT-hNav1.5 plasmid
(a)
(b)
(c)
(d)
(e)
Figure 2 R878C mutation of SCN5A
sodium channel. (a) Sequencing of
SCN5A mutation: heterozygotic mutation
C ﬁ T transition at nucleotide 2826.
(b) Missense mutation of R878C.
(c) Position of R878C on Nav1.5 channel.
(d–e) Alignment analysis of Nav channel
isoforms. R878 is a residue that is highly
conserved in Nav channel isoforms (d)
and among Scn5a in different rat, mouse
and human species (e).
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plasmid, known to increase hNav1.5 expression (Qu
et al. 1995, Xiao et al. 2000, Herfst et al. 2003) and
might be involved in the trafﬁcking or membrane
insertion of the Na
+ channels. (Fig. 3b,f). In contrast,
cells transfected with R878C-hNav1.5 plasmid DNA
(n = 20) did not show any detectable iNa whether in the
absence (Fig. 3c,f) or presence of b1-subunit plasmid
(Fig. 3d,f). Secondly, similar results were obtained in a
second independent expression system produced by
injection of R878C-hNav1.5 cRNA into Xenopus
oocytes studied using a two-microelectrode voltage
clamp technique. In these experiments, all the different
cRNAs were each diluted to a standard concentration of
0.04 ng lL
)1. Furthermore, Na
+ currents were detect-
able even following injection of WT-hNav1.5 cRNA
made to a 50–100-fold dilution. In contrast, Na
+
currents were undetectable even following injection of
R878C-hNav1.5 cRNA prepared undiluted at a
1.5 lg lL
)1.
The alterations in Na
+ channel function critically depend
on the R878 residue
These ﬁndings thus suggest that substitution of the
hydrophilic positively charged arginine with the hydro-
phobic uncharged amino acid cysteine results in a loss
of detectable channel function. However, residue 878 in
Nav1.5 is located at the extracellular linker between S5
and S6 of domain II (DII), a critical region that forms
part of the channel pore. There is therefore the
possibility that arginine has a more speciﬁc role than
simply providing a positive charge inﬂuencing the local
electrostatic ﬁeld essential for channel function. Such a
notion would be consistent with a comparison of
aligned amino acid sequences that demonstrate that
R878 is highly conserved among Nav channel isoforms
(Fig. 2d,e). This hypothesis was explored by expressing
another mutant hNav1.5 construct in which the arginine
R878 was replaced by the similarly positively charged
lysine (K) to give the substitution R878K, through
transient transfection into HEK293 cells. Figure 3e,f
shows that such cells also failed to produce any
detectable iNa (n = 9).
WT-hNav1.5 function persists in the presence of
R878C-hNav1.5
The Xenopus expression system was then used to
quantitatively explore the possible effects of gene
dosage and for the presence or absence of any interac-
tions between WT and mutant gene expression. This
was achieved by introduction of different combinations
of a standard dose of cRNAs encoding each protein
variant. The initial experiments explored the effects of
identical dosages of cRNA encoding WT-hNav1.5 and
mutant R878C-hNav1.5 in different combinations to
determine the time course, peak amplitude and voltage
dependence of the resulting whole-cell Na
+ currents.
The results of the experiments indicated that the size
of iNa is simply related to the dose of WT-hNav1.5
cRNA: the mutant R878C-hNav1.5 is non-functional
WT-hNav1.5
50 mV
30 ms
–120 mV
WT-hNav1.5 + b1
R878C-hNav1.5
R878C-hNav1.5 + b1
R878K-hNav1.5 100 pA/pF
5 ms
300
400
500
600
p
A
/
p
F
0
100
200
WT-
hNav1.5 
WT-
hNav1.5 +
b1
R878C-
hNav1.5 
R878C-
hNav1.5 +
b1
R878K-
hNav1.5 
(a)
(b)
(c)
(d)
(e)
(f)
Figure 3 Characterization of iNa of WT and mutant chan-
nels in HEK293 cells. Inset: HEK293 ells were clamped at a
holding potential of )120 mV and subjected to test voltage
steps each lasting 30 ms that were made to membrane poten-
tials between )110 and +50 mV in 5 or 10 mV increments and
imposed at a pulsing frequency of 1.0 Hz. (a, b) WT-hNav1.5
and WT-hNav1.5 with b1 subunit. (c, d) Mutant R878C-
hNav1.5 and mutant R878C-hNav1.5 with b1 subunit.
(e) Substitution of R878K. (f) Bar graph summarizing peak iNa
(pA pF
)1) in each of the experimental situations above.
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the presence or absence of mutant cRNA neither
increases nor decreases the net size of iNa. Accordingly,
the effects of R878C-hNav1.5 were not dependent
upon the dominant negative effects of the R878C-
hNav1.5 mutation on the function of WT-hNav1.5
on an otherwise normal WT-hNav1.5 expression.
First, injections of cRNAs encoding (WT-hNav1.5 +
H2O) (Fig. 4b) and (WT-hNav1.5 + R878C-hNav1.5)
(Fig. 4c) resulted in similar magnitudes of peak iNa.
These were in turn doubled by the doubled dose
resulting from injection of cRNA encoding (WT-
hNav1.5 + WT-hNav1.5) (Fig. 4a). Secondly, the char-
acteristics of WT-hNav1.5 channels were not affected
by co-expression with R878C-hNav1.5. Thus, key
parameters describing the voltage dependences of the
resulting iNa were indistinguishable whether WT
hNav1.5 were expressed in the presence or absence
of R878C-hNav1.5. Thus the empirical quantiﬁcation
in Table 2 displays statistically identical transition
voltages, similar to normal values reported on earlier
occasions (Zimmer et al. 2002a,b) for inactivation
and activation, Vh and Vm as well as inactivation time
constants sh at membrane potentials of )35, )25 and
)15 mV, and fast, sfast and slow, sslow, recovery
time constants obtained from oocytes injected with
WT-hNav1.5 + H2O and WT-hNav1.5 plus R878C-
hNav1.5 respectively.
Thirdly, previous papers have reported that incuba-
tion with class I anti-arrhythmic agents restored expres-
sion of iNa in an otherwise functional mutant for
I1660V Na
+ channels that have similarly been related to
a Brugada phenotype (Cordeiro et al. 2006). Similar
procedures also restored K
+ channel function in similar
genetically modiﬁed systems (Rajamani et al. 2002,
Valdivia et al. 2004, Anderson et al. 2006). However,
in the present study, the observed alterations in function
persisted in cells treated with class I anti-arrhythmic
agents, that would have restored expression in the event
of a trafﬁcking phenotype. Such experiments studied
HEK293 cells expressing R878C-hNav1.5 that either
had been cultured with 200 lm mexiletine for 24 h, or
transiently exposed to acute administration of either
200 lm mexiletine or 100 lm lidocaine. In both cases,
cells were restored to their normal buffer, with a full
washout of any pharmacological agents 30 min before
patch-clamp recording, neither of which demonstrated
any detectable iNa current. Pre-treatment with mexile-
tine and lidocaine thus failed to result in a recovery of
Na
+ currents in HEK293 cells transfected with R878C -
hNav1.5 channels.
Confocal microscopy results are consistent with persistent
surface localization of R878C-hNav1.5 channels
Finally, confocal microscopy results appeared consistent
with a persistent surface membrane expression of
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Figure 4 Characterization of peak current amplitudes of WT
and mutant channels in Xenopus oocytes. Injection of R878C-
hNav1.5 cRNA did not alter the current amplitude through
WT-hNav1.5 channels (compare WT-hNav1.5 + H2O with
WT-hNav1.5 + R878C-hNav1.5). In control experiments, we
conﬁrmed that a twofold higher WT-hNav1.5 cRNA concen-
tration (WT-hNav1.5 + WT-hNav1.5) resulted in the respective
increase in the peak current amplitude. Number of measure-
ments was between 13 and 35, number of oocyte batches was
at least 3.
Table 2 Electrophysiological properties of WT-hNav1.5 channels co-expressed with R878C-hNav1.5 in Xenopus oocytes
Channel
Steady-state
inactivation
Steady-state
activation Inactivation time constants (sh) Recovery time constants (srec)
Vh (mV) nV m (mV) n
)35 mV
(ms)
)25 mV
(ms)
)15 mV
(ms) n sfast
sslow
(ms)
n
(ms)
WT-hNav1.5 )64.5  0.4 6 )33.1  1.0 5 3.2  0.7 2.0  0.2 1.5  0.1 5 54.4  0.3 97  18 5
WT-hNav1.5/
R878C-hNav1.5
)64.1  0.6 9 )33.2  0.6 9 2.9  0.4 1.7  0.2 1.3  0.1 6 63.6  0.2 105  12 5
Inactivation and recovery curves were ﬁtted mono-exponentially yielding sh and bi-exponentially yielding sfast and sslow respectively.
Data are represented as mean  SEM.
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cells, consistent with continued trafﬁcking of mutant
channels to the plasma membrane, as opposed to a
disrupted trafﬁcking of an otherwise functionally nor-
mal channel.
These studies ﬁrst transfected HEK293 cells with
pEGFP-WT-hNav1.5 and pEGFP-R878C-hNav1.5 con-
structs respectively. The plasma membrane localization
of both WT and mutant channels were then conﬁrmed
by extracellular application of a novel E3-targeted anti-
Nav1.5 antibody (Xu et al. 2005) raised against the
domain 3 extracellular loop of hNav1.5. Figure 5Aa,Ba
conﬁrms successful GFP expression of WT-hNav1.5
(Fig. 5Aa), R878C-hNav1.5 (Fig. 5Ba) and staining of
the ﬂuorescent Cy3-conjugated secondary antibody
(Fig. 5A,B, panel b) respectively. The latter conﬁrms
successful surface membrane expression of WT-
hNav1.5 and R878C-hNav1.5. The resulting overlays
(Fig. 5Ac,Bc) of these confocal images (Fig. 5Aa and b,
and Ba and b) conﬁrm an extracellular location of the
expressed protein in both WT-hNav1.5 and R878C-
hNav1.5-expressing cells. These results suggest a persis-
tent trafﬁcking and expression of mutant channel
R878C-hNav1.5 to the plasma membrane. Secondly,
studies were next made of the expression and intracel-
lular location in HEK293 cells co-transfected with
plasmids for pECFP-WT-hNav1.5 and pEYFP-R878C-
hNav1.5. Exposure to their respective excitation wave-
lengths conﬁrmed that both WT-hNav1.5-CFP
(Fig. 5Ca) and R878C-hNav1.5-YFP (Fig. 5Cb) were
co-expressed. Furthermore the overlaid images further
demonstrated that the two variants had similar subcel-
lular localizations (Fig. 5Cc). These ﬁndings are also
consistent with a normal trafﬁcking of the R878C-
hNav1.5 channel. Taken together these ﬁndings suggest
that the loss of Na
+ current resulting from the R878C
mutation reﬂects loss of function of normally expressed
Na
+ channels rather than altered trafﬁcking of other-
wise functional channels.
Computational analysis of possible functional
consequences of the R878C mutation in SAN
pacemaker function
The biophysical studies above suggest that expression
systems generated by the introduction of cRNA for
R878C-hNav1.5 channel in place of WT-hNav1.5 in
Xenopus oocytes show a corresponding reduction in the
size of Na
+ current. This would predict that heterozyg-
otes for this mutation show a 50% reduction in
expression of functional Na
+ channels. This possible
effect of alterations in iNa on pacemaker rate that might
thereby explain the clinical phenotypes was assessed in
computer simulations based upon an established gradi-
ent model of the intact SAN and atrium (Fig. 6a,b)
(Zhang et al. 2000, Lei et al. 2005). The modelling
assumed a SAN centre of radius 1.5 mm that contained
a uniform density of tetrodotoxin (TTX)-sensitive
neuronal Na
+ channels, and began by assuming that
these would give a maximum current of 10 pA pF
)1.
The surrounding SAN periphery was assumed to have
an annular radius of 1.5 mm and to contain both
WT-hNav1.5-GFP 
5 μm 
R878C-hNav1.5-GFP 
5 μm 
WT-hNav1.5-GCFP + 
R878C-hNav1.5-GYFP 
5 μm 
A  a  b  c 
a  b  c 
a  b  c 
B 
C
Figure 5 Surface membrane localization of SCN5A persists despite the R878C mutation. GFP ﬂuorescence in HEK293 cells of
WT-hNav1.5 (Aa) and R878C-hNav1.5 (Ba) and membrane staining of the ﬂuorescent Cy3-conjugated E3-targeted anti-Nav1.5
antibody (Ab and Bb) and overlays (Ac and Bc) of these confocal images. Expression and intracellular location following
co-transfection with plasmids for pECFP-WT-hNav1.5 and pEYFP-R878C- hNav1.5: exposure to their respective excitation
wavelengths conﬁrms co-expression of both WT-hNav1.5-CFP (Ca) and R878C hNav1.5-YFP (Cb) with similar subcellular
localizations as reﬂected in the overlaid images (Cc). Scale bars = 5 lm for all panels.
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+ channels at a density that
increased towards the periphery giving maximum cur-
rents from 10 to 60 pA pF
)1 towards the periphery.
Remaining ionic current densities were as reported
previously for rabbit SAN (Honjo et al. 1996, 1999, Lei
et al. 2000, 2001). The AP was ﬁrst initiated in the SAN
centre, then allowed to propagate towards its periphery
and into the atrial muscle (Lei et al. 2007). Numerical
simulations were then used to investigate the effect of
progressively reducing iNa density selectively both in the
SAN centre and in the SAN periphery adjacent to the
atrium. Figure 6c conﬁrms a continuous decline in the
resulting heart rates between 100% and 70% expres-
sion of gNa beyond which there was a complete failure
of pacemaker activity. Nevertheless, 50% reductions
in gNa did produce appreciable reductions in heart rate
comparable to the clinical observations.
Discussion
This study describes the physiological correlates of
clinical ﬁndings within the pedigree of a Chinese family
within which a novel mutation (R878C) of the hNav1.5
channel was identiﬁed for the ﬁrst time. Detailed
genomic analysis was correlated with results from full
clinical examinations of available family members. The
same mutation was also screened in 200 controls with
normal cardiovascular histories and clinical and ECG
examinations and the same ethnic background. DNA
sequencing of all the SCN5A exons and exon–intron
boundaries revealed a novel heterozygous base change
in exon 16 (2826 C ﬁ T) that would be expected to
result in substitution of an arginine in residue 878. This
amino acid residue R878 is likely to be critical for Na
+
channel function. Thus, alignment analysis indicated
that R878 is a residue in domain II of S5-S6 that shows
a highly conserved arginine residue amongst Nav
channel isoforms. Furthermore, R878 is located in the
pore-forming region of domain II close to the selectivity
ﬁlter DEKA and a highly conserved EEDD ring of
charge (Xiong et al. 2006).
The four family members who proved to be mutation
carriers on genetic analysis in the present study showed
a range of phenotypic characteristics that variously
appeared in childhood (proband) and adult life (uncle of
the proband). All of these have nevertheless been
associated with cardiac Na
+ channel mutations on
previous occasions. This is in contrast to our recent
report of a simpler clinical picture presenting a full and
similar penetrance in a family pedigree showing LQT2
(Zhang et al. 2007). Thus, a comparison of ECG
characteristics suggested a signiﬁcant slowing of SA,
atrioventricular and intraventricular conduction and a
signiﬁcant incidence of sinus bradycardia consistent
with SSS and persistent ST elevation in carriers when
these were compared with non-carriers from the same
family. The present report adds a novel Na
+ channel
variant to the four mutations within the same domain II
S5-S6 region, S871fs+9X, F891I, S896S and S910L, that
have already been described (Priori et al. 2002). All of
these were also missense mutations. However, these
merely resulted in BrS (Priori et al. 2002). Furthermore,
earlier studies did not observe the wide range of ECG
changes or pursue the fuller cellular functional studies
reported here.
These ﬁndings nevertheless also add a novel Na
+
channel variant to available recent reports that have
associated SCN5A mutations with a range of pheno-
types extending even to SSS (Bezzina et al. 1999,
Veldkamp et al. 2000, Benson et al. 2003, Groenewe-
gen et al. 2003, Makiyama et al. 2005, Remme et al.
2006). There have been 13 previous SCN5A mutations
associated with familial SSS by itself or in combination
(a)
(b)
(c)
Figure 6 Results of computational modelling of sino-atrial
(SA) node function as a result of the R878C mutation. (a)
Toluidine blue-stained tissue section through the SA node
and its surrounding atrial muscle of the crista terminalis cut
through the leading pacemaker site of the rabbit heart. (b)
Model of the SA node and its surrounding atrium. (c) Com-
puter simulations of the effect on pacemaker activity by
reduction in Na
+ channel function.
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these, two occurred with a gain of function, ﬁve a loss of
function and four appeared to result in a total absence
of iNa in common with the mutation described here (Lei
et al. 2007). Six heterozygous SCN5A mutations have
been associated with an autosomal recessive congenital
SSS with complete penetrance also associated with
conduction disorders including evidence for latent
atrioventricular conduction system disease. Two of
these mutations produced non-functional Na
+ channels
when expressed in stable mammalian cells (Benson
et al. 2003). These clinical features correlated with
reports from experimental studies in heterozygous
Scn5a
+/)mouse models with a targeted heterozygous
disruption of Scn5a (Papadatos et al. 2002, Lei et al.
2005). Such reports directly implicated Nav1.5 channel
currents in arrhythmic phenomena at widespread car-
diac sites. These included the conduction of APs
through the SAN, from the SAN to atrial muscle, and
within the ventricles. They also suggested that these
have indirect effects in the maintenance of normal SAN
pacemaker rhythm and rate (Lei et al. 2005).
The functional consequences of the R878C Nav1.5
mutation reported here were then investigated by
biophysical and modelling studies. Both HEK293 cells
and Xenopus oocytes were used as complementary
expression systems. Normal Na
+ currents were observed
following expression of WT-hNav1.5 channels in both
HEK293 or oocyte cells, the latter even following
injection of a 50- to 100-fold dilution of WT-hNav1.5
cRNA. Such iNa was observed even with co-expression
of half the dose of WT-hNav1.5 cRNA. In contrast,
patch-clamp recordings in either HEK293 cells trans-
fected with the construct or voltage-clamped Xenopus
oocytes injected with cRNA encoding the R878C-
hNav1.5 channel failed to show detectable iNa, even
where undiluted cRNA was used for oocyte injection.
Furthermore, the presence of such Na
+ channel function
was highly dependent on and speciﬁc to the residue
R878. Thus, transfection of the hNav1.5 construct,
containing a similarly positively charged lysine to give
the substitution R878K, into HEK293 cells did not
recover Na
+ channel function. These ﬁndings comple-
ment previous reports of highly conserved positions that
were critical for channel function. Thus insertion of
aspartate (1795insD) in the carboxy terminus of
SCN5A can result in either BrS or LQTS (Bezzina et al.
1999, Veldkamp et al. 2000), and mutation of the same
residue to a histidine (Y1795H) or cysteine (Y1795C)
also results in BrS and LQTS respectively. These
previous ﬁndings indicate the proximal region of the
C-terminus as potentially important in Na
+ channel
function (Rivolta et al. 2001). Our study points out that
R878 is similarly highly conserved, and that the
replacements of either R878C or R878K failed to
produce any detectable iNa despite both amino acids
carrying similar positive charge.
To test for the effect of the simultaneously produced
R878C-hNav1.5 mutant on the expression of WT-
hNav1.5 in Xenopus oocytes, we co-injected equal
amounts of the respective cRNAs into oocytes and
determined the peak current amplitudes and kinetic
parameters of the whole-cell Na
+ currents. R878C-
hNav1.5 did not exert dominant negative phenotypic
effects: iNa was simply determined by the amount of
WT-hNav1.5 cRNA. Doubling the dose of WT-hNav1.5
cRNA doubled iNa. iNa amplitudes and activation and
inactivation characteristics were similar with WT-
hNav1.5 cRNA given alone or in combination with
equal doses of R878C-hNav1.5 cRNA. Furthermore,
steady-state activation, steady-state inactivation, inac-
tivation time constants and recovery from inactivation
were indistinguishable in WT-hNav1.5 plus R878C-
hNav1.5 vs. WT-hNav1.5 channels. These data indicate
that the mutant R878C is non-functional also in the
presence of WT channels and that WT-hNav1.5 kinetics
is not affected.
Additional biophysical and immunochemical exper-
iments provided further evidence that the presence of
the mutation probably resulted in a persistent expres-
sion of non-functional Na
+ channels, as opposed to
abolishing the trafﬁcking of otherwise functionally
normal channels to the cell surface membrane. Thus
Na
+ channel function in HEK293 cells with R878C-
hNav1.5 was not restored by transient exposure to
either mexiletine (200 lm) or lidocaine (100 lm),
manoeuvres that have previously been used to restore
channel trafﬁcking (Rajamani et al. 2002, Valdivia
et al. 2004, Anderson et al. 2006, Cordeiro et al.
2006). In the above respects, our studies complement
earlier reports from the four heterozygous SCN5A
mutations T187I, D356N, K1578fs/52, and R1623X
that were similarly linked with BrS, SSS and atrioven-
tricular block mentioned above (Makiyama et al. 2005).
All these also resulted in non-functional channels, an
absence of any dominant negative effects on WT
channels and in which iNa was also not restored by
mexiletine (Makiyama et al. 2005), suggesting that the
changes may be a general consequence of mutations
in SCN5A. Furthermore, extracellular application of
E3-targeted anti-Nav1.5 antibody yielded a signiﬁcant
plasma membrane expression of both WT and mutant
channels. This suggests a persistent expression of mutant
but non-functional Na
+ channels despite the complete
abolition of Na
+ currents in the homozygote, consistent
with a continued expression of non-functional channels
rather than a total failure of expression of otherwise
normal channels.
As the affected members in the family concerned were
heterozygotes, one would expect that Na
+ currents in
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50%, i.e. corresponding to the level of WT-hNav1.5
channels produced from the unaffected allele. Numer-
ical modelling demonstrated the effects upon SAN
function as reﬂected in heart rate of a progressive
reduction in Nav1.5 current resulting from increasing
proportions of non-functional mutant channels in an
established model of SAN-atrium tissue (Zhang et al.
2000, Lei et al. 2005). This produced graded reductions
in heart rate at least over the reduction region of iNa as
seen in clinical cases, whose physiological correlates are
examined here.
In conclusion, we have identiﬁed and characterized a
novel mutation at a highly conserved pore residue in
domain II S5-S6 of the cardiac type Na
+ channel in a
three-generation Chinese family that complements pre-
vious studies reporting a range of, rather than a single
clinical, phenotype.
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